COMBACTE LAB-Net: building a European laboratory network for clinical trials on anti-infectives
LAB-Net, the laboratory network of COMBACTE, has established itself as an indispensable network for clinical trials in infectious diseases that plays a crucial part across 30 clinical studies not only within, but also outside the COMBACTE consortium. Since its official launch in January 2013, LAB-Net has expanded more than threefold and in Q4 2020 it encompasses 841 labs across 41 countries in Europe. In addition, LAB-Net has crossed the European borders and collaborates with more than 300 laboratories spread across the globe. The tight collaboration with partners within COMBACTE and beyond contributed tremendously to the growth of LAB-Net over the years. A sustainable infrastructure beyond COMBACTE-NET is needed to ensure the smooth handover and continuity of the achievements made by the project.
Read publication
Related media library items
Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study
Background Clinical data characterizing invasive Escherichia coli disease (IED) are limited. We assessed the clinical presentation of IED and antimicr...
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study
Purpose Invasive Escherichia coli disease (IED) encompasses a diverse range of sterile site infections. This study evaluated the feasibility of captur...
Postoperative Staphylococcus aureus Infections in Patients With and Without Preoperative Colonization
Key Points Question What is the cumulative incidence of Staphylococcus aureus surgical site infections (SSIs) and bloodstream infections (BSIs) in Eu...